Fig. 2: Kaplan–Meier analyses of progression-free survival in the intent-to-treat population (n = 275 patients). | Nature Communications

Fig. 2: Kaplan–Meier analyses of progression-free survival in the intent-to-treat population (n = 275 patients).

From: Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial

Fig. 2: Kaplan–Meier analyses of progression-free survival in the intent-to-treat population (n = 275 patients).

A Investigator-assessed and B Blinded Independent Central Review-assessed. HR hazard ratio. The hazard ratio (HR) was derived from a stratified Cox proportional hazards model, and the one-sided p-value was derived from the Log-Rank test. Source data are provided as a Source Data file.

Back to article page